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Transcriptional repressionidence that the transcription factor BCL11B represses expression from the HIV-1
long terminal repeat (LTR) in T lymphocytes through direct association with the HIV-1 LTR. We also
demonstrate that the NuRD corepressor complex mediates BCL11B transcriptional repression of the HIV-1
LTR. In addition, BCL11B and the NuRD complex repressed TAT-mediated transactivation of the HIV-1 LTR in T
lymphocytes, pointing to a potential role in initiation of silencing. In support of all the above results, we
demonstrate that BCL11B affects HIV-1 replication and virus production, most likely by blocking LTR
transcriptional activity. BCL11B showed speciﬁc repression for the HIV-1 LTR sequences isolated from seven
different HIV-1 subtypes, demonstrating that it is a general transcriptional repressor for all LTRs.
© 2008 Elsevier Inc. All rights reserved.Introduction
Expression of the Human Immunodeﬁciency Virus Type 1 (HIV-1)
genes is controlled by the 5′ long terminal repeat (LTR) and by viral
and host transcription factors which bind to DNA response elements
localized within this region (Greene, 1990; Klotman et al., 1991;
Pereira et al., 2000). The viral transactivator protein Tat plays a critical
role in activation of transcription from the LTR (Gaynor, 1995; Jeang,
Shank, and Kumar, 1988; Kao et al., 1987; Pereira et al., 2000). In
addition, numerous cellular transcription factors were found to
regulate transcription from the LTR, including Sp1 (Demarchi et al.,
1993; Garcia et al., 1987; Kamine, Subramanian, and Chinnadurai,
1991; Schwartz et al., 2000), NF-kB (Bounou, Dumais, and Tremblay,
2001; Demarchi et al., 1993; Mukerjee et al., 2007; Perkins et al., 1993;
Podolin and Prystowsky, 1991), NFAT (Demarchi et al., 1993; GifﬁnB; CLL, chronic lymphocytic
, electrophoretic mobility shift
an immunodeﬁciency virus 1;
eling and deacetylase; MTA1,
TSA, trichostatin A.
t.
t as senior authors.
l rights reserved.et al., 2003), HMG protein (Sheridan et al., 1995), C/EBP (Dumais
et al., 2002; Henderson, Zou, and Calame, 1995; Mukerjee et al.,
2007), AP-1, Ets-1, LEF-1, and YY1 (cited in Gaynor, 1992; Pereira
et al., 2000). Nuclear hormone receptors, including COUP-TF, were
also demonstrated to participate in the transcriptional activation
from the LTR (Rohr et al., 2000; Schwartz et al., 2000).
Participation of cellular transcriptional regulators in HIV-1 silen-
cing is of major interest, as this process can be implicated in virus
latency. Previously, HMGB1 (Naghavi et al., 2003) and BCL11B (CTIP2)
(Marban et al., 2005, 2007; Rohr et al., 2003) were found to repress
transcription from the LTR. However, the studies on BCL11B-mediated
transcriptional repression of the LTR were conducted by overexpres-
sing BCL11B in microglial cells (Marban et al., 2005, 2007; Rohr et al.,
2003). Microglial cells are immune cells of myeloid origin present in
the central nervous system (Hickey and Kimura, 1988). In the immune
system BCL11B is speciﬁcally and restrictively expressed in T
lymphocytes (Cismasiu et al., 2005, 2006; Wakabayashi et al., 2003a,
2003b). CD4+ T lymphocytes are an important target for HIV-1
infection and the role of BCL11B in transcriptional control of HIV-1 LTR
in these cells has not been addressed before.
BCL11B is a C2H2 zinc ﬁnger transcriptional regulator required for T
cell development, both at beta selection checkpoint at the DN3 stage
(Wakabayashi et al., 2003b), and in positive selection of double
positive (DP) thymocytes (Albu et al., 2007). Additionally, BCL11B was
Fig. 1. Sustained BCL11B expression in Jurkat cells represses the HIV-1 LTR activity. (A)
Western blot analysis of nuclear extracts from Jurkat cells stably transduced with
retroviruses expressing GFP (MSCV) and the small splice variant of BCL11B (asterisk),
Flag-BCL11B-IRES-GFP, (MSCV:Flag-BCL11B) (Cismasiu et al., 2006). (B) Jurkat-MSCV
and Jurkat-MSCV:Flag-BCL11B cells were transfected with the HIV-1 LTR-luciferase
construct, and the cellular extracts were subsequently analyzed for luciferase activity as
previously described (Cismasiu et al., 2006). The asterisk indicates signiﬁcant statistical
difference (Pb0.05) between Jurkat-MSCV and Jurkat-MSCV:Flag-BCL11B. This is a
representative experiment of three with similar results.
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(DN) and DP thymocytes (Albu et al., 2007;Wakabayashi et al., 2003b).
At the molecular level BCL11B has been shown previously to elicit
transcriptional repression when tethered to promoters through the
COUP-TF nuclear receptors and heterologous DNA binding domains
(Avram et al., 2000) or through direct binding of its own response
elements (Avram et al., 2002; Cismasiu et al., 2005). We previously
demonstrated, using unbiased approaches, that the endogenous
BCL11B complexes are associated with the corepressor complex
NuRD in CD4+ T lymphocyte, and that these complexes harbor histone
deacetylase (HDAC) activity sensitive to trichostatin A (TSA), an
inhibitor of the NuRD HDACs (Cismasiu et al., 2005). We also
demonstrated that the NuRD components MTA1 and MTA2 directly
interact with BCL11B, allowing the recruitment of the NuRD complex
to targeted promoters (Cismasiu et al., 2005).
As CD4+ T lymphocytes represent a major target for HIV infection,
as well as a source of virus (Dalgleish et al., 1984), it is of interest
whether BCL11B regulates LTR activity in these cells as well. In this
study, we provide evidence that the HIV-1 LTR is a target for BCL11B
transcriptional repression and that the NuRD components MTA1, and
to a lesser extent MTA2, augmented the transcriptional repression of
the HIV-1 LTR by BCL11B. In addition, BCL11B–NuRD complex
repressed the transactivation mediated by TAT on HIV-LTR, results
which support the implication of BCL11B–NuRD complex in initiation
of silencing of HIV-LTR. Endogenous BCL11B and the NuRD complex
were found to associate with the integrated HIV-1 LTR in CD4+ Tlymphocytes, therefore directly implicating BCL11B and the NuRD
complex in the transcriptional repression of HIV-1 gene expression in
T lymphocytes. Importantly, this study also demonstrates that the
BCL11B-mediated transcriptional repression of the LTR is well-
conserved over different HIV-1 subtypes, and further, suggests that
the interaction of BCL11B with the LTR could be exploited for a novel
anti-retroviral therapy.
Results
Enhanced expression of BCL11B in Jurkat T lymphocytes represses
transcription from the LTR
BCL11B was previously demonstrated to repress expression from
the HIV-1 LTR, when overexpressed in microglial cells (Marban et al.,
2005, 2007; Rohr et al., 2003). However, BCL11B has restricted
expression to T lymphocytes within the immune system, and its
expression is excluded from B lymphocyte or myeloid lineages
(Cismasiu et al., 2005, 2006; Wakabayashi et al., 2003a, 2003b).
How BCL11B acts on the HIV-1 LTR in T lymphocytes has never been
addressed. To determine whether BCL11B is implicated in the
transcriptional regulation of LTR in human T lymphocytes, we
employed the Jurkat T cells stably transduced with retroviruses
expressing GFP (Jurkat) and Flag-BCL11B-IRES-GFP (Jurkat-BCL11B)
(Cismasiu et al., 2006). Populations of cells were sorted based on GFP
expression, expanded and tested for the presence of Flag-BCL11B
(Fig. 1A). Jurkat-BCL11B and Jurkat cells were further transfected
with HIV-1 LTR-luciferase construct. Results revealed that over-
expression of BCL11B signiﬁcantly repressed the expression from the
HIV-1 LTR (Fig. 1B), demonstrating that BCL11B plays a role in the
repression of HIV-1 LTR expression in T cells.
Repression mediated by BCL11B on the HIV-1 LTR is augmented by the
NuRD component MTA1, and to a lesser extent by MTA2
We previously demonstrated that BCL11B and the NuRD complex
associate in Jurkat T lymphocytes (Cismasiu et al., 2005). We also
demonstrated that the NuRD components MTA1 and MTA2 mediate
the interaction of BCL11B with the NuRD complex (Cismasiu et al.,
2005). To demonstrate that the NuRD complex functionally partici-
pates in the transcriptional repression mediated by BCL11B we
conducted luciferase reporter assays in which HeLa cells were
transfected with HIV-LTR-reporter, BCL11B and the components of
the NuRD complex MTA1 and MTA2 (Cismasiu et al., 2005). BCL11B
repressed the HIV-1 LTR reporter activity (Fig. 2, lane 5). MTA1 (Fig. 2,
lane 6), and to a lesser extent MTA2 (Fig. 2, lane 7), augmented the
repression function of BCL11B on HIV-LTR activity. However the effect
was not synergistic (Fig. 2, lane 8). The LTR repression was dependent
on the presence of BCL11B, as neither MTA1 nor MTA2 alone (Fig. 2,
lanes 2, 3 and 4), repressed the HIV-LTR at signiﬁcant levels.
These results taken together implicate BCL11B and the NuRD
complex in silencing of HIV expression.
Knockdown of BCL11B and MTAs results in derepression of HIV-LTR
To further demonstrate that endogenous BCL11B plays a role in the
repression of HIV-1 LTR, 1G5 Jurkat cells, endogenously expressing
BCL11B and containing an HIV-LTR-luciferase expression cassette
integrated into the genome (Aguilar-Cordova et al., 1994), were
transfected with BCL11B siRNA. Knockdown of BCL11B (Fig. 3B)
resulted in signiﬁcant derepression of HIV-1 LTR (Fig. 3A), demon-
strating that endogenous BCL11B plays a role in silencing of this
promoter. Further, knockdown ofMTA1 orMTA2 (Fig. 3B) also resulted
in derepression of HIV-1 LTR (Fig. 3A).
These results taken together show that endogenous BCL11B and
the NuRD complex exert a silencing effect on the HIV-1 LTR.
Fig. 2. Transcriptional repression of the HIV-1 LTR by BCL11B is augmented by MTA1, and to a lesser extent by MTA2 of the NuRD complex. (A) Luciferase assays from HeLa cells
transfected with HIV-1 LTR-luciferase and β-gal (lanes 1–8), BCL11B (lanes 5–8), MTA1 (lanes 2, 4, 6 and 8) andMTA2 (lanes 3, 4, 7 and 8). This is a representative experiment of three
with similar results. The asterisks indicate that the samples in lanes 6, 7 and 8 are statistically different (Pb0.05) from the sample in lane 5. (B) Western blot analysis of nuclear
extracts of HeLa cells transfected with either MTA1 or MTA2.
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Because HIV TAT plays a critical role in transcription from the HIV-
LTR (Benkirane et al., 1998; Jeang, Shank, and Kumar, 1988; Kao et al.,
1987; Nekhai and Jeang, 2006), we investigated the impact of BCL11B
and the associated NuRD complex on HIV-LTR transactivation by TAT,Fig. 3. Knockdown of BCL11B results in derepression of HIV-LTR. (A) 1G5 Jurkat cells, contain
transfected with the indicated siRNAs and the extracts were analyzed for luciferase activity. T
2, 3 and 4) relative to control siRNA (lane 1). The asterisks indicate that the samples in lanes
analysis of nuclear extracts from 1G5 Jurkat cells transfected with the indicated siRNAs.to determine whether BCL11B and the associated NuRD complex can
initiate silencing in conditions when HIV-LTR is activated by TAT. For
this purpose 1G5 Jurkat cells were co-transfected with HIV TAT,
BCL11B, MTA1 or MTA2. Our results show that BCL11B signiﬁcantly
repressed TAT-mediated transcriptional activation of the HIV-1 LTR
(Fig. 4). MTA1 signiﬁcantly augmented the repression mediated bying the HIV-LTR-luciferase expression cassette stably integrated into the genome, were
he Y-axis represents percent derepression of luciferase activity in siRNA samples (lanes
2, 3 and 4 are statistically different (Pb0.05) from the sample in lane 1. (B) Western blot
Fig. 5. Knockdown of BCL11B and the NuRD components MTA1 and MTA2 reduces the
transactivation of HIV-LTR by TAT. 1G5 Jurkat cells were transfected with TAT and the
indicated siRNAs, harvested at 48 h post-transfection and analyzed for luciferase
activity. The Y-axis represents percent luciferase activity of speciﬁc siRNA samples
(lanes 2, 3 and 4) versus siRNA control (lane 1). The asterisks indicate that the samples
in lanes 2, 3 and 4 are statistically different (Pb0.05) from the sample in lane 1.
Fig. 4. BCL11B and MTA1 inhibit TAT-mediated transactivation of HIV-1 LTR. 1G5 Jurkat
cells were co-transfected with HIV Tat, BCL11B, MTA1 and MTA2 plasmids as indicated.
Cells were collected at 48 h post-transfection and analyzed for luciferase activity. The Y-
axis represents percent inhibition of luciferase activity relative to the Tat alone (lane 1).
The asterisks indicate that the samples in lanes 2 and 3 are statistically different
(Pb0.05) from the sample in lane 1.
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BCL11B-mediated repression of HIV-LTR (Fig. 4). These results, as well
as the data above and bellow, suggest that MTA1 is the preferred
partner of BCL11B in the transcriptional repression of HIV-LTR, as
previously suggested by our published data (Cismasiu et al., 2005).
To demonstrate that indeed the endogenous BCL11B plays a role in
the repression of HIV-1 LTR when activated by TAT, 1G5 Jurkat cells
were transfected with TAT and BCL11B siRNA. Knockdown of BCL11B
resulted in a signiﬁcant increase of TAT-mediated transactivation of
HIV-1 LTR (Fig. 5), demonstrating that endogenous BCL11B plays a role
in initiation of silencing of TAT-activated HIV-LTR. Knockdown of
MTA1 or MTA2 also resulted in a signiﬁcant increase of TAT-mediated
transactivation of HIV-1 LTR, revealing that the NuRD complex plays a
role in initiation of silencing from TAT-activated HIV-LTR (Fig. 5).
These results taken together show that BCL11B and the NuRD
complex play a role in initiation of silencing of TAT-activated HIV-LTR,
in addition to exerting a silencing effect on the HIV-1 LTR in the
absence of TAT.
BCL11B and the NuRD complex associate with the integrated HIV-LTR in
Jurkat T lymphocytes
Following infection, the HIV-1 DNA is integrated into the host
genome and the HIV-1 LTR is organized into chromatin (reviewed in
He et al., 2002;Marzio and Giacca,1999). Chromatinization of the HIV-
1 LTR creates a transcriptionally inactive state, which contributes to
the establishment and maintenance of latency in the absence of any
stimulation (He et al., 2002; Lusic et al., 2003). We therefore
investigated whether endogenous BCL11B is present on the integrated
HIV-1 LTR in 1G5 Jurkat T lymphocytes and consequently participates
in the silencing of the promoter. In the absence of any stimulation, the
activity of this promoter is reduced, however it increases signiﬁcantly
as a result of viral infection (Aguilar-Cordova et al., 1994 and Fig. 6A,).
Immunoprecipitation of the crosslinked extracts from uninfected 1G5
cells with anti-BCL11B (B26-44) antibodies signiﬁcantly enriched the
HIV-1 LTR, (Fig. 6B upper panel). Immunoprecipitation of the cross-
linked extracts from infected cells resulted in signiﬁcantly less
enrichment of the HIV-1 LTR (Fig. 6B, lower panel), compared to
uninfected cells. Therefore, these results suggest that BCL11B ispredominantly associated with the silenced HIV-1 LTR from unin-
fected cells, however a small fraction of BCL11B still remains
associated with the HIV-LTR even in infected cells.
Because BCL11B is known to associate with the NuRD complex we
wanted to investigate whether the NuRD complex is also present on
the HIV-1 LTR promoter. We therefore conducted immunoprecipita-
tion of the crosslinked extracts from uninfected 1G5 cells with the
NuRD complex antibodies and our results show that the HIV-LTR was
highly enriched in the NuRD-IP-ed complex from uninfected, and to a
lesser extent from infected cells (Fig. 6C). These results therefore show
that the NuRD complex is also present on HIV-1 LTR, predominantly in
uninfected cells, but a fraction still remains on the promoter even in
infected cells.
All these data taken together show that BCL11B and the NuRD
complex are associated with the HIV-1 LTR, predominantly in
uninfected cells, however a small fraction is also associated with the
HIV-1 LTR in infected cells.
BCL11B directly binds the HIV-1 LTR
The HIV-1 LTR contains several BCL11B consensus response
elements. We already demonstrated by ChIP assays the association
of BCL11B with the HIV-1 LTR, however another transcription factor
may mediate this interaction. We therefore investigated whether
BCL11B may exert its transcriptional repression function on HIV-1
expression by direct binding to the HIV-1 LTR. To test the direct
binding of BCL11B to the HIV-1 LTR we employed electrophoretic
mobility shift assays (EMSA) using bacterially expressed and puriﬁed
GST-BCL11B. The results clearly showed that GST-BCL11B 356–812,
which contains the carboxyl zinc ﬁngers involved in DNA binding
(Fig. 6, lane 3), but not GST (Fig. 6, lane 2), bound the HIV-1 LTR, but not
a control nonspeciﬁc DNA of a similar size covering the BCL11B ORF
(data not shown). Addition of excess cold BCL11B RE oligo competitor
abolished binding (Fig. 6, lane 5), while addition of a nonspeciﬁc oligo
Fig. 6. Endogenous BCL11B and the NuRD complex associatewith the HIV-1 LTR in Jurkat 1G5 cells and BCL11B directly binds HIV-1 LTR in vitro. (A) 1G5 Jurkat cells were infectedwith
NL4-3 (white bar) or mock (black bar) and the luciferase activity was evaluated at 3 days after infection. (B) Chromatin immunoprecipitation with anti-BCL11B antibody (B26–44)
(lane 3) or IgG (lane 2) of nuclear extracts from uninfected (upper panel) or infected (lower panel) Jurkat 1G5 cells. (C) Chromatin immunoprecipitations with the NuRD antibodies
anti-HDAC2 and -MTA1 (lane 3) or IgG (lane 2) from uninfected (upper panel) and infected (lower panel) 1G5 nuclear extracts. In B and C lane 1 represents the input which in all cases
was 0.2%. (D) Electrophoretic mobility shift assays (EMSA): [32P]HIV-1 LTR fragment (HIV-LTR−326–+62) probe was incubated with GST (lane 2) or GST-BCL11B 356–812 (lanes 3–5)
in the presence of cold BCL11B response element oligos (lane 4) or noncompetitive oligos (lane 5). BCL11B–[32P] HIV-1 LTR complexes are indicated by an interrupted arrow and the
free probe is indicated by a continuous arrow.
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binding. These results taken together clearly show that BCL11B directly
binds to the HIV-1 LTR in vitro, therefore suggesting that the HIV-1 LTR
may potentially be a direct target for BCL11B.
Overexpression of BCL11B inhibits viral replication of infectious HIV-1
Todemonstrate that transcriptional repressionmediated byBCL11B
translates into inhibition of infectious virionproduction,we conducted
experiments testing whether BCL11B inhibits viral replication of
infectious HIV-1 in Tcells. Jurkat and Jurkat-BCL11B cells were infected
with HIVNL4–3, and the infected cell culture medium was analyzed for
the amount of infectious virus produced at various times post-
infection (Fig. 7A). In addition, at peak virus production, the infected
cell populationswere analyzed for intracellular expression of p24 virus
capsid protein, as a measure of virus production by individual cells
(Fig. 7B). Our results demonstrate that overexpression of BCL11B
strongly inhibited HIVNL4–3 virus replication and production, and
rendered the Jurkat-BCL11B cells much less permissive for productive
infection compared to Jurkat cells, suggesting that LTR transcriptional
repression byBCL11B results in reduced viral replication andproduction.
Knockdown of BCL11B and MTA1 enhances viral replication and
production
Conversely, when BCL11B was downregulated by siRNA prior to
HIV-1 infection, the infected cell populations showed higherintracellular expression of p24 virus capsid protein compared to
siRNA control, indicating that in the absence of BCL11B viral
replication is enhanced (Fig. 8A). In addition, knockdown of MTA1,
but not MTA2, resulted in a signiﬁcant increase in the intracellular
levels of p24 virus capsid protein in infected cells, demonstrating
that the reduction of MTA1 of the NuRD also favors viral
replication. In addition, the infected cell culture medium was
analyzed for the amount of infectious virus produced post-infection
and the results show that knockdown of BCL11B and MTA1, but not
MTA2, led to a signiﬁcant increase of the amount of virus in the
media (Fig. 8B).
These results taken together suggest that the LTR transcriptional
repression by endogenous BCL11B and the NuRD complex translates in
control of viral replication and virus production.
BCL11B represses LTR sequences of seven HIV-1 subtypes
As BCL11B consensus sites in the U3 modulatory region of the HIV-
1 LTR are conserved throughout different HIV-1 subtypes (data not
shown), we wanted to determine whether BCL11B transcriptional
repression is conserved within the isolated subtypes. For this purpose
HeLa cells were co-transfected with each of the A-G LTR-luciferase
constructs, and increasing amounts of BCL11B DNA, and analyzed for
LTR activity by luciferase assays. BCL11B showed speciﬁc transcrip-
tional repression for LTRs A-G with no effect on the basal control
promoter (pGL3) expression (Fig. 9). All subtypes testedwere sensitive
to concentration-dependent BCL11B repression, presenting
Fig. 7. T cells overexpressing BCL11B are nonpermissive for HIVNL4–3 infection. (A) Jurkat and Jurkat-BCL11B cells were infected at an MOI=0.1 and subsequently analyzed for
infectious virus production by GHOST assay at the indicated time points post-infection, (B) as well as for intracellular p24 virus capsid protein expression by ﬂow cytometry at 6 days
post-infection. Graphs shown are representative of 3 independent infection experiments with similar results.
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and suggesting that BCL11B is a general transcriptional repressor for
all tested HIV-1 LTRs.
Discussion
It has been established by previous studies that following
infection of susceptible cells, HIV-1 DNA is integrated into the host
genome and the LTR is organized into chromatin (reviewed in He
et al., 2002; Marzio and Giacca, 1999). Transcription of the HIV-1
provirus is regulated by viral and cellular transcription factors,
which bind to sites in the HIV-1 LTR (reviewed in Pereira et al.,
2000). However, chromatinization of the HIV-1 LTR creates a
transcriptionally inactive state of the proviral promoter, which
contributes to the establishment and maintenance of latency in the
absence of any stimulation (He et al., 2002; Lusic et al., 2003).
Based on the data reported here BCL11B and the NuRD complex
may play a role in the generation of a silenced state of chromatin
on the integrated HIV-1 promoter in T lymphocytes, and potentially
on other integrated retroviral promoters. Though BCL11B and the
NuRD complex are predominantly present on the HIV-LTR in the
absence of infection, a small fraction of BCL11B–NuRD complex is
still present on the promoter in conditions of infection. Knockdown
of endogenous BCL11B and MTA1 resulted in increased activity ofthe TAT transactivator, and also enhanced virus replication and
production in a spreading infection, thus supporting the role of
endogenous BCL11B and NuRD complex in the repression of TAT-
mediated transactivation from HIV-1 LTR in T cells, and in initiating
of HIV-1 LTR silencing in T lymphocytes. Moreover, in conditions
when the integrated promoter was activated by TAT, the addition
of BCL11B repressed the TAT-mediated transactivation, suggesting
again that BCL11B–NuRD complex is capable of initiating silencing
in T lymphocytes. In conclusion, our results suggest that BCL11B
acts on the HIV-1 LTR by two mechanisms. Under conditions
conducive to LTR activation, such as during infection, a small
fraction of BCL11B–NuRD complex is associated with the HIV-1 LTR.
This small fraction is not sufﬁcient to completely block the
expression of the promoter when Tat is present. However, the
complex does exert a level of control on TAT-mediated LTR
transactivation, demonstrated by the fact that knockdown of
BCL11B results in enhancement of transactivation mediated by
TAT. The small fraction of BCL11B–NuRD complex present on the
promoter under conditions favoring activation may play a role in
“priming” the promoter for silencing. Thus, binding of additional
BCL11B can initiate silencing by recruitment of more NuRD
complex, which our results suggest is likely to occur through a
mechanism by which BCL11B directly binds to the promoter. It is
unlikely that BCL11B directly competes with TAT in binding the
Fig. 8. Knockdown of BCL11B enhances HIV-1 replication in a spreading infection. (A)
siRNA-transfected SUPT-1 cells were infected with HIVNL4–3 (MOI=0.1) and infected cell
populations were analyzed by ﬂow cytometry for percent of cells positive for
intracellular p24 expression at 5 days post-infection. The asterisks indicate that
BLC11B siRNA and MTA1 siRNA samples are statistically different (Pb0.05) from control
siRNA sample. (B) Cell-free supernatants from the cultures in panel A were collected at
5 days post-infection and used to infect GHOST cells. The numbers of EGFP-expressing
cells were counted, and the infectious virus titer of each culture was calculated. The
asterisks indicate that BLC11B siRNA and MTA1 siRNA samples are statistically different
(Pb0.05) from control siRNA sample.
Fig. 9. BCL11B represses LTR (A–G) activity in a dose-dependent manner. Luciferase
assays from HeLa cells transfected with 0.5 μg HIV-LTR (A–G)-luciferase DNA and either
0.05, 0.5, or 1 μg of BCL11B DNA. The luciferase activity was normalized to the activity of
each LTR construct in the absence of any added BCL11B DNA. The asterisks indicate that
the samples transfected with speciﬁc amounts of BCL11B are statistically different
compared to the corresponding sample lacking BCL11B. The graph is representative of
3–5 independent experiments.
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binding sites of BCL11B do not resemble the Tar loop, which is the
binding site of TAT (Avram et al., 2002), but rather through
creation of unfavorable conditions for TAT binding. The increase in
recruitment of the NuRD complex by BCL11B to the HIV-1 LTR
results in subsequent deacetylation of histones and very likely
restricts the association of both viral and cellular transcriptional
activators with the promoter. The NuRD complex possesses both
histone deacetylase and ATP-dependent nucleosome remodeling
activities (Xue et al., 1998; Zhang et al., 1999), which allow the
generation of a transcriptionally nonpermissive environment on
targeted promoters (Liu and Bagchi, 2004; Xue et al., 1998; Zhang
et al., 1999). During conditions favoring silencing, a larger fraction
of BCL11B–NuRD complex is associated with HIV-1 LTR, likely
playing a role in maintaining HIV-1 LTR silencing. These two roles
of endogenous BCL11B–NuRD complex in HIV-1 transcriptional
silencing in T lymphocytes come in addition to the BCL11B-
mediated inhibition of TAT transactivation function through
redistribution to the heterochromatin compartment in microglial
cells as a result of BCL11B overexpression (Rohr et al., 2003).
Overall, our results suggest a preference of BCL11B to use MTA1–
NuRD complex, as previously suggested by our published data
(Cismasiu et al., 2005).
In HeLa cell models, other transcription factors such as YY1 and LSF
were previously shown to cooperatively recruit HDAC1 to the
integrated HIV-1 LTR which resulted in decreased expression fromthe HIV-1 LTR, hence implicating histone deacetylation in transcrip-
tional repression of the integrated provirus and establishment of
latency (Coull et al., 2000; He and Margolis, 2002). In microglial cells
in conditions of overexpression of BCL11B, repression of HIV-1 LTR
was found to directly recruit HDAC deacetylases without the
requirement of the NuRD complex (Marban et al., 2007). However
our results in T lymphocytes, which, unlike microglial cells, normally
express BCL11B, demonstrate the presence of the NuRD complex on
the HIV-1 LTR.
Herewe implicate the NuRD complex in associationwith BCL11B in
silencing of HIV-1 gene expression in T lymphocytes, and potentially
in silencing of other viruses. In this respect it is of interest that
individual components of the NuRD complexwere previously found to
regulate viral activities by associationwith viral proteins. For example,
HDAC1 was shown to associate with the human T-cell leukemia virus
type 1 (HTLV-1) Tax oncoprotein, to negatively regulate viral gene
expression (Ego, Ariumi, and Shimotohno, 2002). Other examples
include the human papilloma virus E7 protein, which was shown to
associate with Mi2 of the NuRD complex to promote cell growth
(Brehm et al., 1999), and the Epstein–Barr virus nuclear antigen 3C,
which was shown to associate with HDAC1 in relation to viral latency
(Radkov et al., 1999).
Viral strains belonging to several major subtypes (A–G) isolated
from various infected populations worldwide have LTR sequences
which differ by 5–20%, which may account for differences in their
transcriptional activity (De Arellano, Soriano, and Holguin, 2005;
Jeeninga et al., 2000). These LTR sequence differences may account for
differences in clinical outcome (De Arellano, Soriano, and Holguin,
2005; Hiebenthal-Millow et al., 2003; Jeeninga et al., 2000; Naghavi
et al., 1999; van Opijnen et al., 2004). Our results demonstrate that
BCL11B represses expression from all seven LTR subtype sequences
tested, suggesting that BCL11B is a general transcriptional repressor
for all major HIV-1 LTRs andmay be involved in HIV-1 latency. Though
consensus BCL11B binding sites exist in all of the subtypes studied,
there are also variations, which may account for the slight differences
in the transcriptional repression observed among the subtypes. The
BCL11B-mediated transcriptional repression across many virus sub-
types demonstrates a global LTR transcriptional repression activity for
BCL11B, and suggests a possible novel therapeutic approach against
HIV-1 disease. Since BCL11B expression is limited to T lymphocytes
and neurons, it may be possible to augment current HAART therapies
by development of a small molecule to stabilize BCL11B and NuRD
complex binding to the LTR, and thus increase the transcriptional
repression and implicitly inhibition of replication mediated by this
host factor. Alternatively, if BCL11B is involved in virus latency, a
180 V.B. Cismasiu et al. / Virology 380 (2008) 173–181periodic inhibition of BCL11B binding might decrease the pool of
latently infected cells during chronic HIV infection.
Materials and methods
Plasmids
BCL11B, MTA1 and MTA2 clones were previously described
(Cismasiu et al., 2005). pBlue3′LTR-luc containing LAI 3′ HIV-1 LTR
(Klaver and Berkhout, 1994) was obtained through the AIDS Research
and Reference Reagent Program (Division of AIDS, National Institute of
Allergy and Infectious Disease, NIH).
Cell culture, transfections and reporter assays
Jurkat cells were obtained from ATCC. The following cell lines were
obtained though the AIDS Research and Reference Reagent Program
(Division of AIDS, National Institute of Allergy and Infectious Disease,
NIH): Jurkat 1G5 cells (Aguilar-Cordova et al., 1994), Sup-T1 T cells
(Smith et al., 1984) and GHOST-X4/R5 cells (Morner et al., 1999).
Jurkat, Sup-T1 and A293T cells were grown as previously described
(Cismasiu et al., 2005; Duus et al., 2001). Transfections and reporter
assays were conducted as previously described (Cismasiu et al., 2005,
2006).
siRNA silencing experiments
Control, BCL11B, MTA1 orMTA2 siRNAs and their transfectionwere
previously described (Cismasiu et al., 2005, 2006). HIV-1NL4–3 stocks
were produced by transfection of A293T cells, as previously described
(Duus et al., 2001). Jurkat/Jurkat-BCL11B and Sup-T1 cells were
infected with stock virus at a multiplicity of infection (MOI)=0.1, or
mock-infected for 2 h, grown in freshmedium and analyzed at speciﬁc
time points post-infection. Productively infected cells were analyzed
for intracellular p24 by ﬂow cytometry, and infectious virus release
was analyzed by GHOST assay. GHOST cell HIV-1 Titer Assay was
conducted as previously described (Morner et al., 1999).
Antibodies
Anti-BCL11B (B26–44), MTA1 and MTA2 antibodies were pre-
viously described (Cismasiu et al., 2005, 2006). Anti-p24 clone KC57
conjugated to FITC was from Beckman Coulter.
Chromatin immunoprecipitation (ChIP)
1G5 Jurkat cells containing the HIV-1 LTR-luciferase integrated into
the genome (Aguilar-Cordova et al., 1994) were used for ChIP assays
which were conducted as previously described (Cismasiu et al., 2005,
2006). In the case of the NuRD complex ChIP, prior to crosslinkingwith
formaldehyde, the cells were crosslinked with dimethyl 3,3′-dithio-
bispropionimidate (DTBP) (Pierce), to assure crosslinking of the
proteins in the complex. DTBP, an imidoester crosslinker with longer
effective distance than formaldehyde, efﬁciently crosslinks proteins
and was previously used successfully to crosslink components of the
NuRD complex (Fujita et al., 2003; Fujita and Wade, 2004). The
following primers crossing HIV-LTR −326 through +62 were used for
ampliﬁcation of the HIV-1 LTR: forward: 5′-cactgacctttggatggtgc-3′
and reverse: 5′-aggcttaagcagtgggttcc-3′.
Electrophoretic mobility shift assays (EMSA)
DNA binding experiments were conducted as previously described
(Avram et al., 2002; Cismasiu et al., 2006). GST fusion proteins were
expressed in the BL21 (DE3) plysS strain of E. coli and puriﬁed on
glutathione Sepharose-4B (Pharmacia) using standard techniques.Statistical analysis
The Student T-test was used for statistical analysis and differences
were considered signiﬁcant when P values were b0.05.
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